BioCentury
ARTICLE | Company News

NantPharma licenses Amgen's AMG 337

September 15, 2015 12:57 AM UTC

Amgen Inc. (NASDAQ:AMGN) granted NantPharma LLC exclusive, worldwide rights to develop and commercialize AMG 337, excluding Japan, Russia and certain countries in central Asia. NantPharma is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.).

AMG 337 is a small molecule inhibitor of c-MET receptor tyrosine kinase that is in Phase II to treat gastric and esophageal cancers. NantPharma said it will select clinical trial patients based on molecular profiling. ...